title: Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).
abstract: BACKGROUND
  Probiotics are effective in inflammatory bowel diseases. Clinical effectiveness and dose dependency of E. coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC).
  
  
  METHODS
  In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to treatment with either 40, 20, or 10 ml enemas (N = 24, 23, 23) containing 10E8 EcN/ml or placebo (N = 20). The study medication was taken once daily for at least 2 weeks. After 2, 4 and/or 8 weeks the clinical DAI was assessed together with tolerance to treatment. Patients who reached clinical DAI <or= 2 within that time were regarded as responders.
  
  
  RESULTS
  According to ITT analysis the number of responders was not significantly higher in the EcN group than in the placebo group (p = 0.4430, 2-sided). However, the Jonckheere-Terpstra rank correlation for dose-dependent efficacy indicated a significant correlation of per-protocol responder rates (p = 0.0446, 2-sided). Time to remission was shortest with EcN 40 ml, followed by EcN 20 ml. The number of adverse events did not differ notably.
  
  
  CONCLUSIONS
  In contrast to ITT analysis, efficacy of rectal EcN application was significant in PP and points to EcN as a well tolerated treatment alternative in moderate distal UC.
  
  
  BACKGROUND
  German Clinical Trials Register DRK00000234.
authors.affiliation: Department of Gastroenterology, Community Hospital Havelhoehe, Kladower Damm 221, 14089 Berlin, Germany. hmatthes@havelhoehe.de
authors.forename: Harald
authors.initials: H
authors.lastname: Matthes
authors.forename: Thomas
authors.initials: T
authors.lastname: Krummenerl
authors.forename: Manfred
authors.initials: M
authors.lastname: Giensch
authors.forename: Corinna
authors.initials: C
authors.lastname: Wolff
authors.forename: Jürgen
authors.initials: J
authors.lastname: Schulze
mesh_terms: D000208:Acute Disease; D000285:Administration, Rectal; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000008:administration & dosage / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004733:Enema; D004926:Escherichia coli; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001688:Biological Products
references.citation: MMW Fortschr Med. 2006 Aug 31;148(35-36):30-4
references.pmid: 16995360
references.citation: Eur J Gastroenterol Hepatol. 2003 Jun;15(6):697-8
references.pmid: 12840682
references.citation: BMJ. 2006 Aug 12;333(7563):340-3
references.pmid: 16902215
references.citation: Br Med J. 1956 Jun 9;1(4979):1315-8
references.pmid: 13316140
references.citation: Lancet. 1999 Aug 21;354(9179):635-9
references.pmid: 10466665
references.citation: Aliment Pharmacol Ther. 1999 Aug;13(8):1103-8
references.pmid: 10468688
references.citation: Gastroenterology. 1987 Jun;92(6):1894-8
references.pmid: 3569765
references.citation: Gut. 2005 Jun;54(6):782-8
references.pmid: 15888785
references.citation: Curr Gastroenterol Rep. 2007 Oct;9(5):434-40
references.pmid: 17991347
references.citation: Inflamm Bowel Dis. 1998 May;4(2):79-83
references.pmid: 9589293
references.citation: Dig Dis Sci. 2007 Nov;52(11):2926-9
references.pmid: 17404867
references.citation: Res Microbiol. 2003 Jan-Feb;154(1):59-66
references.pmid: 12576161
references.citation: Nihon Rinsho. 2005 May;63(5):845-9
references.pmid: 15881180
references.citation: Aliment Pharmacol Ther. 1997 Oct;11(5):853-8
references.pmid: 9354192
references.citation: Mol Nutr Food Res. 2008 Aug;52(8):906-12
references.pmid: 18384087
references.citation: Nephron. 2002 Sep;92(1):200-2
references.pmid: 12187103
references.citation: Infect Immun. 2004 Oct;72(10):5750-8
references.pmid: 15385474
references.citation: World J Gastroenterol. 2006 Oct 14;12(38):6115-23
references.pmid: 17036381
references.citation: J Bacteriol. 2004 Aug;186(16):5432-41
references.pmid: 15292145
references.citation: Z Klin Med. 1951 Feb 15;2(3-4):68
references.pmid: 14800874
references.citation: J Am Coll Nutr. 2003 Feb;22(1):56-63
references.pmid: 12569115
references.citation: Scand J Gastroenterol. 2007 Nov;42(11):1306-11
references.pmid: 17852859
references.citation: Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:64-7
references.pmid: 16961748
references.citation: J Gastroenterol Hepatol. 2007 Feb;22(2):261-7
references.pmid: 17295881
references.citation: Infect Immun. 2007 May;75(5):2399-407
references.pmid: 17283097
references.citation: Mol Nutr Food Res. 2008 Aug;52(8):898-905
references.pmid: 18383235
references.citation: Ann N Y Acad Sci. 2006 Aug;1072:339-50
references.pmid: 17057214
references.citation: Gastroenterology. 2007 Feb;132(2):763-86
references.pmid: 17258735
references.citation: Postgrad Med J. 2006 Oct;82(972):620-5
references.pmid: 17068271
references.citation: Am J Gastroenterol. 2005 Feb;100(2):355-61
references.pmid: 15667493
references.citation: Gut. 2004 Nov;53(11):1617-23
references.pmid: 15479682
references.citation: Neth J Med. 2007 Dec;65(11):411-8
references.pmid: 18079563
references.citation: J Clin Microbiol. 2006 Sep;44(9):3172-7
references.pmid: 16954244